Screening of antigenic vesicular fluid proteins of Echinococcus multilocularis as potential viability biomarkers to monitor drug response in alveolar echinococcosis patients

Benoit Valot (1) , Bénédicte Rognon (1, 2) , Anais Prenel (1) , Alice Baraquin (1) , Jenny Knapp (1, 2) , Mathilde Anelli (1) , Carine Richou (3, 4) , Solange Bresson-Hadni (1, 4) , Frederic Grenouillet (1, 2) , Junhua Wang (5, 6) , Dominique Angèle Vuitton (4) , Bruno Gottstein (6) , Laurence Millon (1, 2)

1 LCE - Laboratoire Chrono-environnement (UMR 6249)
2 Service de parasitologie et mycologie [CHRU de Besançon]
3 Service d'Hépatologie [CHRU Besançon]
4 WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis
5 LCFC - Laboratoire de Conception Fabrication Commande
6 Institute of Parasitology

The only drugs available to treat alveolar echinococcosis (AE) are mostly parasitostatic and in many cases prescribed for life. Decision criteria for discontinuation rely on the absence of parasitic viability. The aim of the present study is to search for candidate proteins that may exhibit good potential as biomarkers for viability.

Mots clés: Alveolar echinococcosis; immunoproteomics; vesicular fluid; viability biomarker

Domaines: Santé

Benoit Valot, Bénédicte Rognon, Anais Prenel, Alice Baraquin, Jenny Knapp, et al.. Screening of antigenic vesicular fluid proteins of Echinococcus multilocularis as potential viability biomarkers to monitor drug response in alveolar echinococcosis patients. PROTEOMICS - Clinical Applications, 2017, ⟨10.1002/prca.201700010⟩. ⟨hal-01667558⟩